Business Wire

Export-Friendly Virtual Simulator to Be Displayed by Meggitt Training Systems at Security & Counter Terror Expo

Del

Meggitt Training Systems, the leading provider of integrated live-fire and virtual weapons training products and services for armed forces and law enforcement, will demonstrate its export-friendly FATS® 100MIL small-arms training system at Security & Counter Terror Expo (SCTX). The national security event will be held March 6-7, 2018 at Olympia in London.

Meggitt Training Systems’ FATS 100MIL enabled program-of-record wins for the US Army Engagement Skills Trainer (EST II) and the US Marine Corps Indoor Simulated Marksmanship Trainer (ISMT). Meggitt will demonstrate the system with a variety of weapons, including those based on the company’s BlueFire® wireless technology, the company’s first time exhibiting at SCTX.

“The FATS 100MIL is the result of constant innovation and experience garnered through the delivery and support of 5,100 virtual systems worldwide,” said Mark Mears, European general manager for Meggitt Training Systems. “Customers in the United States, United Kingdom, Italy, Canada, Singapore, Australia, Belgium and elsewhere have chosen Meggitt to fulfill their stringent virtual training requirements.”

The FATS 100MIL is a major expansion in weapons training capability, introducing revolutionary features such as advanced game engine 3D marksmanship, enhanced diagnostics with intelligent automatic coaching and collective training. The new system provides an impressive array of functionality for both instructor and trainee, delivering solid weapon-handling and shot-placement analytics, coaching tools that automatically highlight trainee results for reinforcement or correction, and enhanced graphic capabilities for an all-encompassing immersive training platform.

During the past year, Meggitt has expanded its virtual simulation offerings by introducing the FATS 100P portable training system, featuring full marksmanship and video-based judgmental training capabilities in a compact form factor. It also announced the FATS 300MIL, which provides a five-screen, 300-degree immersive experience for realistic marksmanship, collective and judgmental training. Finally, the company debuted its Live-Fire Screen that brings all the benefits of virtual training to an indoor shooting range or shoot house, thanks to the use of a self-healing rubber screen designed to withstand 50,000 rounds before replacement.

To see a FATS 100MIL demonstration and speak with a Meggitt representative during Security & Counter Terror Expo, visit stand B40 or schedule an appointment at https://meggitttrainingsystems.com/about/request-a-meeting-with-meggitt-training-systems/.

About Meggitt Training Systems

Meggitt Training Systems, makers of FATS® and Caswell technologies, a division of Meggitt PLC, is the leading supplier of integrated live-fire and virtual weapons training systems. Following the acquisition of FATS® virtual training systems and Caswell International’s live-fire ranges and services, Meggitt Training Systems has continued to grow its capabilities based on the legacy of these two industry leaders. Over 13,000 Meggitt live-fire ranges and 5,100 virtual systems are fielded internationally, providing judgmental, situational awareness and marksmanship training to the armed forces, law enforcement and security organizations.

Meggitt Training Systems employs more than 400 people at its headquarters in Atlanta and at facilities in Orlando, Canada, the United Kingdom, Netherlands, UAE, Australia and Singapore. It can deploy service personnel anywhere in the world for instructor training, system installation and maintenance.

About Meggitt PLC

Headquartered in the United Kingdom, Meggitt PLC is an international group operating in North America, Europe and Asia. Known for its specialized extreme environment engineering, Meggitt is a world leader in aerospace, defense and energy, employing nearly 11,000 people at more than 50 manufacturing facilities and regional offices worldwide.

Contact information

Meggitt Training Systems
Michelle Henderson, 678-288-1090
michelle.henderson@meggitt.com
www.MeggittTrainingSystems.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58Pressemelding

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs